Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
GENE's Cash to Debt is ranked higher than
97% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.07 vs. GENE: No Debt )
GENE' s 10-Year Cash to Debt Range
Min: 6.33   Max: No Debt
Current: No Debt

Equity to Asset 0.68
GENE's Equity to Asset is ranked higher than
72% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. GENE: 0.68 )
GENE' s 10-Year Equity to Asset Range
Min: 0.67   Max: 0.88
Current: 0.68

0.67
0.88
F-Score: 4
Z-Score: -12.20
M-Score: -3.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -108.70
GENE's Operating margin (%) is ranked higher than
56% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. GENE: -108.70 )
GENE' s 10-Year Operating margin (%) Range
Min: -313.93   Max: 5.73
Current: -108.7

-313.93
5.73
Net-margin (%) -110.95
GENE's Net-margin (%) is ranked higher than
56% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. GENE: -110.95 )
GENE' s 10-Year Net-margin (%) Range
Min: -496.89   Max: 4.98
Current: -110.95

-496.89
4.98
ROE (%) -164.92
GENE's ROE (%) is ranked lower than
55% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. GENE: -164.92 )
GENE' s 10-Year ROE (%) Range
Min: -168.88   Max: 13.76
Current: -164.92

-168.88
13.76
ROA (%) -111.75
GENE's ROA (%) is ranked lower than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. GENE: -111.75 )
GENE' s 10-Year ROA (%) Range
Min: -112.85   Max: 10.2
Current: -111.75

-112.85
10.2
ROC (Joel Greenblatt) (%) -2153.43
GENE's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. GENE: -2153.43 )
GENE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2153.43   Max: 110.44
Current: -2153.43

-2153.43
110.44
EBITDA Growth (%) -12.60
GENE's EBITDA Growth (%) is ranked higher than
58% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. GENE: -12.60 )
GENE' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 26
Current: -12.6

0
26
» GENE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
GENE's P/B is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.83 vs. GENE: 2.70 )
GENE' s 10-Year P/B Range
Min: 0.58   Max: 25.5
Current: 2.7

0.58
25.5
P/S 2.70
GENE's P/S is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. GENE: 2.70 )
GENE' s 10-Year P/S Range
Min: 0.88   Max: 64
Current: 2.7

0.88
64
EV-to-EBIT -1.91
GENE's EV-to-EBIT is ranked lower than
58% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GENE: -1.91 )
GENE' s 10-Year EV-to-EBIT Range
Min: 27.5   Max: 121
Current: -1.91

27.5
121
Current Ratio 1.08
GENE's Current Ratio is ranked lower than
53% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. GENE: 1.08 )
GENE' s 10-Year Current Ratio Range
Min: 1.08   Max: 5.22
Current: 1.08

1.08
5.22
Quick Ratio 0.99
GENE's Quick Ratio is ranked lower than
51% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. GENE: 0.99 )
GENE' s 10-Year Quick Ratio Range
Min: 0.99   Max: 5.22
Current: 0.99

0.99
5.22

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.40
GENE's Price/Tangible Book is ranked higher than
84% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.75 vs. GENE: 3.40 )
GENE' s 10-Year Price/Tangible Book Range
Min: 2.25   Max: 24.75
Current: 3.4

2.25
24.75
Price/Median PS Value 0.50
GENE's Price/Median PS Value is ranked higher than
97% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. GENE: 0.50 )
GENE' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 15.25
Current: 0.5

0.38
15.25
Forward Rate of Return (Yacktman) -27.78
GENE's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.81 vs. GENE: -27.78 )
GENE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -94   Max: -24
Current: -27.78

-94
-24

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:GTG.Australia, GNTLF.USA, DU8.Germany
Genetic Technologies Limited is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents globally; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.
» More Articles for NAS:GENE

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Why Genetic Technologies (GENE) Stock Is Spiking Today Jul 07 2014
Genetic Technologies provides BREVAGen revenue update Jul 07 2014
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014 Jul 07 2014
Appendix 3B Jun 27 2014
Genetic Technologies appoints Eutillio Buccilli as CFO May 29 2014
Genetic Technologies Announces Appointment of Chief Financial Officer May 28 2014
Genetic Technologies Announces Completion of Share Transaction With Dr. Mervyn Jacobson May 16 2014
Genetic Technologies Files Activities Report for the Quarter Ended March 31, 2014 Apr 30 2014
Results From Extraordinary General Meeting Apr 17 2014
Genetic Technologies Executes Agreement With Promega Corporation Mar 24 2014
5 Stocks Ready for Breakouts Mar 21 2014
Genetic Technologies Announces Publication of Economic Modeling Study Supporting Cost-Effectiveness... Mar 07 2014
Genetic Technologies Provides Further Update on Corporate Structure Feb 24 2014
Genetic Technologies Announces Update on Intellectual Property Feb 12 2014
Genetic Technologies Provides Corporate and Financial Update for Quarter Ended December 31, 2013 Jan 30 2014
Appendix 3B Jan 20 2014
Genetic Technologies Announces New Record Growth in Number of BREVAGen(TM) Tests Received for... Jan 08 2014
Licensing Update Dec 24 2013
Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds Dec 23 2013
Issue of Redeemable Convertible Note and Receipt of Funds Dec 23 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide